14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
GRX vs GUT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
GRX Captures Overall Composite Edge (41.3 SELL vs 41.1 SELL), While GUT Leads 1–0 on Growth & Valuation Pillars
GRX Overall Winner
6-Pillar Tally: GRX 0 – 1 GUT (5 Tie)
Matrix Metrics: GRX 2 – 1 GUT
As of Nov 16, 2026, The Gabelli Healthcare & Wellness Trust (GRX) captures the overall head-to-head institutional edge over Gabelli Utility Trust (GUT) on higher Unified Composite conviction (41.3/100 SELL vs. 41.1/100 SELL) after splitting the core matrix 2–1 (led by composite factor balance), while GUT wins 1–0 across the 6-pillar growth and valuation breakdown. GRX trades at $10.58 (N/M Forward P/E, N/A operating margin) versus GUT at $5.20 (N/M Forward P/E, N/A operating margin).
Growth vs. Quality Trade-Off: GRX earns the overall head-to-head edge with a stronger Unified Composite Score (41.3/100 SELL vs. GUT 41.1/100 SELL) and 0.14β · 14% Vol risk profile, whereas GUT leads top-line expansion (N/A YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although GRX compares more favorably head-to-head, both GRX (41.3/100 SELL) and GUT (41.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: GRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.1); meanwhile GUT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GRX vs GUT. Trailing 12-month operating profitability (GRX N/A vs GUT N/A) and valuation multiples (GRX N/M vs GUT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with $142.9M market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
GUT Moat ProfileCyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $536.6M market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ GRX vs GUT Key Questions & Quantitative Answers
As of Nov 16, 2026, The Gabelli Healthcare & Wellness Trust (GRX) captures the overall head-to-head institutional edge over Gabelli Utility Trust (GUT) on higher Unified Composite conviction (41.3/100 SELL vs. 41.1/100 SELL) after splitting the core matrix 2–1 (led by composite factor balance), while GUT wins 1–0 across the 6-pillar growth and valuation breakdown. GRX trades at $10.58 (N/M Forward P/E, N/A operating margin) versus GUT at $5.20 (N/M Forward P/E, N/A operating margin). Growth vs. Quality Trade-Off: GRX earns the overall head-to-head edge with a stronger Unified Composite Score (41.3/100 SELL vs. GUT 41.1/100 SELL) and 0.14β · 14% Vol risk profile, whereas GUT leads top-line expansion (N/A YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although GRX compares more favorably head-to-head, both GRX (41.3/100 SELL) and GUT (41.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: GRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.1); meanwhile GUT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GUT leads the Growth & Scale pillar: GRX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with GUT at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, GRX generates N/A in USD-normalized revenue versus N/A for GUT. In operating R&D and SG&A reinvestment, GRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GUT.
GRX and GUT trade at balanced relative valuation multiples. GRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GUT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GRX (N/A ROE) versus GUT (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, GRX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 14% Vol realized risk). By comparison, GUT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 27% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.